J. Safra Sarasin Holding AG Boosts Stock Holdings in Gilead Sciences, Inc. $GILD

J. Safra Sarasin Holding AG boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 22.9% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 897,793 shares of the biopharmaceutical company’s stock after buying an additional 167,263 shares during the quarter. Gilead Sciences makes up about 1.6% of J. Safra Sarasin Holding AG’s holdings, making the stock its 11th largest position. J. Safra Sarasin Holding AG owned about 0.07% of Gilead Sciences worth $99,655,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Phoenix Financial Ltd. increased its holdings in Gilead Sciences by 10.6% in the 3rd quarter. Phoenix Financial Ltd. now owns 11,161 shares of the biopharmaceutical company’s stock worth $1,239,000 after acquiring an additional 1,067 shares during the last quarter. Stonegate Investment Group LLC boosted its position in Gilead Sciences by 2.9% during the third quarter. Stonegate Investment Group LLC now owns 4,190 shares of the biopharmaceutical company’s stock worth $465,000 after purchasing an additional 118 shares during the period. Belpointe Asset Management LLC boosted its position in Gilead Sciences by 2.2% during the third quarter. Belpointe Asset Management LLC now owns 5,671 shares of the biopharmaceutical company’s stock worth $629,000 after purchasing an additional 124 shares during the period. Chilton Capital Management LLC increased its stake in shares of Gilead Sciences by 18.4% in the third quarter. Chilton Capital Management LLC now owns 441,459 shares of the biopharmaceutical company’s stock worth $49,002,000 after purchasing an additional 68,610 shares in the last quarter. Finally, CFS Investment Advisory Services LLC raised its position in shares of Gilead Sciences by 3.1% in the third quarter. CFS Investment Advisory Services LLC now owns 11,441 shares of the biopharmaceutical company’s stock valued at $1,384,000 after purchasing an additional 348 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on GILD shares. Needham & Company LLC upped their price target on shares of Gilead Sciences from $133.00 to $140.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. Argus boosted their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the company a “buy” rating in a report on Tuesday, November 4th. HSBC raised their price target on Gilead Sciences from $110.00 to $133.00 and gave the stock a “hold” rating in a report on Wednesday, December 10th. Wall Street Zen lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research note on Friday. Finally, Rothschild & Co Redburn increased their price objective on Gilead Sciences from $153.00 to $159.00 and gave the stock a “buy” rating in a report on Tuesday, January 20th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $134.52.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $125.86, for a total value of $3,524,080.00. Following the completion of the sale, the insider owned 107,193 shares of the company’s stock, valued at $13,491,310.98. This represents a 20.71% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction that occurred on Friday, November 28th. The shares were sold at an average price of $125.08, for a total transaction of $625,400.00. Following the transaction, the director owned 8,920 shares in the company, valued at $1,115,713.60. The trade was a 35.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 247,397 shares of company stock worth $31,986,612. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Price Performance

GILD stock opened at $137.78 on Tuesday. The firm has a 50 day simple moving average of $124.25 and a two-hundred day simple moving average of $118.88. The stock has a market cap of $170.94 billion, a PE ratio of 21.36, a P/E/G ratio of 0.71 and a beta of 0.33. Gilead Sciences, Inc. has a one year low of $93.10 and a one year high of $138.03. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. The company had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The firm’s revenue was up 3.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.